These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 33610887)

  • 1. Effects of antithrombotic drugs on the prothrombotic state in patients with atrial fibrillation: The west Birmingham atrial fibrillation project.
    Voukalis C; Lip GYH; Shantsila E
    Thromb Res; 2021 Apr; 200():149-155. PubMed ID: 33610887
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Apixaban enhances endogenous fibrinolysis in patients with atrial fibrillation.
    Spinthakis N; Gue Y; Farag M; Srinivasan M; Wellsted D; Arachchillage DRJ; Lip GYH; Gorog DA
    Europace; 2019 Sep; 21(9):1297-1306. PubMed ID: 31505618
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of non-vitamin K antagonist oral anticoagulants on fibrin clot and whole blood clot formation, integrity and thrombolysis in patients with atrial fibrillation.
    Lau YC; Xiong Q; Shantsila E; Lip GY; Blann AD
    J Thromb Thrombolysis; 2016 Nov; 42(4):535-44. PubMed ID: 27554264
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Laboratory assessment of anti-thrombotic therapy in heart failure, atrial fibrillation and coronary artery disease: insights using thrombelastography and a micro-titre plate assay of thrombogenesis and fibrinolysis.
    Lau YC; Xiong Q; Ranjit P; Lip GY; Blann AD
    J Thromb Thrombolysis; 2016 Aug; 42(2):233-44. PubMed ID: 26942726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of fixed low-dose warfarin, aspirin-warfarin combination therapy, and dose-adjusted warfarin on thrombogenesis in chronic atrial fibrillation.
    Li-Saw-Hee FL; Blann AD; Lip GY
    Stroke; 2000 Apr; 31(4):828-33. PubMed ID: 10753983
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of renal function on whole blood and fibrin clot formation in atrial fibrillation patients on warfarin.
    Lau YC; Xiong Q; Lip GY; Blann AD
    Ann Med; 2016; 48(4):275-81. PubMed ID: 27043881
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Apixaban versus warfarin in patients with atrial fibrillation according to prior warfarin use: results from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation trial.
    Garcia DA; Wallentin L; Lopes RD; Thomas L; Alexander JH; Hylek EM; Ansell J; Hanna M; Lanas F; Flaker G; Commerford P; Xavier D; Vinereanu D; Yang H; Granger CB
    Am Heart J; 2013 Sep; 166(3):549-58. PubMed ID: 24016506
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and Safety of Apixaban Versus Warfarin in Patients With Atrial Fibrillation and Extremes in Body Weight.
    Hohnloser SH; Fudim M; Alexander JH; Wojdyla DM; Ezekowitz JA; Hanna M; Atar D; Hijazi Z; Bahit MC; Al-Khatib SM; Lopez-Sendon JL; Wallentin L; Granger CB; Lopes RD
    Circulation; 2019 May; 139(20):2292-2300. PubMed ID: 30773022
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
    Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
    Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of Apixaban on All-Cause Death in Patients with Atrial Fibrillation: a Meta-Analysis Based on Imputed Placebo Effect.
    Guimarães PO; Lopes RD; Wojdyla DM; Abdul-Rahim AH; Connolly SJ; Flaker GC; Wang J; Hanna M; Granger CB; Wallentin L; Lees KR; Alexander JH; McMurray JJV
    Cardiovasc Drugs Ther; 2017 Jun; 31(3):295-301. PubMed ID: 28516318
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost-Utility Analysis of Apixaban versus Warfarin in Atrial Fibrillation Patients with Chronic Kidney Disease.
    Altawalbeh SM; Alshogran OY; Smith KJ
    Value Health; 2018 Dec; 21(12):1365-1372. PubMed ID: 30502779
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes of apixaban vs. warfarin by type and duration of atrial fibrillation: results from the ARISTOTLE trial.
    Al-Khatib SM; Thomas L; Wallentin L; Lopes RD; Gersh B; Garcia D; Ezekowitz J; Alings M; Yang H; Alexander JH; Flaker G; Hanna M; Granger CB
    Eur Heart J; 2013 Aug; 34(31):2464-71. PubMed ID: 23594592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Major bleeding in patients with atrial fibrillation receiving apixaban or warfarin: The ARISTOTLE Trial (Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation): Predictors, Characteristics, and Clinical Outcomes.
    Hylek EM; Held C; Alexander JH; Lopes RD; De Caterina R; Wojdyla DM; Huber K; Jansky P; Steg PG; Hanna M; Thomas L; Wallentin L; Granger CB
    J Am Coll Cardiol; 2014 May; 63(20):2141-2147. PubMed ID: 24657685
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation (ARISTOTLE) trial: design and rationale.
    Lopes RD; Alexander JH; Al-Khatib SM; Ansell J; Diaz R; Easton JD; Gersh BJ; Granger CB; Hanna M; Horowitz J; Hylek EM; McMurray JJ; Verheugt FW; Wallentin L;
    Am Heart J; 2010 Mar; 159(3):331-9. PubMed ID: 20211292
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of apixaban compared with warfarin on coagulation markers in atrial fibrillation.
    Christersson C; Wallentin L; Andersson U; Alexander JH; Alings M; De Caterina R; Gersh BJ; Granger CB; Halvorsen S; Hanna M; Huber K; Hylek EM; Lopes RD; Oh BH; Siegbahn A
    Heart; 2019 Feb; 105(3):235-242. PubMed ID: 30209126
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High-sensitivity troponin T and risk stratification in patients with atrial fibrillation during treatment with apixaban or warfarin.
    Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Alexander JH; Atar D; Gersh BJ; Hanna M; Harjola VP; Horowitz JD; Husted S; Hylek EM; Lopes RD; McMurray JJ; Granger CB;
    J Am Coll Cardiol; 2014 Jan 7-14; 63(1):52-61. PubMed ID: 24055845
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Apixaban for stroke prevention in atrial fibrillation: a review of the clinical trial evidence.
    Yates SW
    Hosp Pract (1995); 2011 Oct; 39(4):7-16. PubMed ID: 22056819
    [TBL] [Abstract][Full Text] [Related]  

  • 18. N-terminal pro-B-type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation).
    Hijazi Z; Wallentin L; Siegbahn A; Andersson U; Christersson C; Ezekowitz J; Gersh BJ; Hanna M; Hohnloser S; Horowitz J; Huber K; Hylek EM; Lopes RD; McMurray JJ; Granger CB
    J Am Coll Cardiol; 2013 Jun; 61(22):2274-84. PubMed ID: 23563134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Association Between Treatment With Apixaban, Dabigatran, Rivaroxaban, or Warfarin and Risk for Osteoporotic Fractures Among Patients With Atrial Fibrillation: A Population-Based Cohort Study.
    Lau WCY; Cheung CL; Man KKC; Chan EW; Sing CW; Lip GYH; Siu CW; Lam JKY; Lee ACH; Wong ICK
    Ann Intern Med; 2020 Jul; 173(1):1-9. PubMed ID: 32423351
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013.
    Olesen JB; Sørensen R; Hansen ML; Lamberts M; Weeke P; Mikkelsen AP; Køber L; Gislason GH; Torp-Pedersen C; Fosbøl EL
    Europace; 2015 Feb; 17(2):187-93. PubMed ID: 25236181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.